

# **First US Plan to Address Alzheimer's Disease**

**Ronald C. Petersen, PhD, MD**  
**Chair**

**Advisory Council on Research, Care and Services  
for the  
National Alzheimer's Project Act**

# **NAPA Advisory Committee**

- **26 members, 14 federal, 12 non-federal**
- **Federal members represent federal agencies involved in Alzheimer's disease in the US**
- **Non-federal members**
  - **Care providers**
  - **Caregivers**
  - **State agencies**
  - **Voluntary health organizations**
  - **Researchers**

**Passed by  
Congress  
2010**

**December**

**Advisory  
Council  
appointed  
2011**

**August**

**Advisory  
Committee  
Meeting  
2012**

**January**

**National  
Plan  
announced  
2012**

**May**

**Advisory  
Committee  
Meeting  
2012**

**October**

## **National Alzheimer's Project Act**

**January  
2011**

**Signed by  
President**

**September  
2011**

**Advisory  
Committee  
Meeting**

**April  
2012**

**Advisory  
Committee  
Meeting**

**July  
2012**

**Advisory  
Committee  
Meeting**

**January  
2013**

**Advisory  
Committee  
Meeting**

# NAPA Process

- **National plan developed by Federal members with input from Advisory Council**
  - Existing resources
- **Separate set of recommendations sent to Secretary Sebelius and Congress**
  - New resources

# National Plan to Address Alzheimer's Disease

<http://aspe.hhs.gov/daltcp/napa/NatlPlan.pdf>



U.S. Department of Health and Human Services  
Office of Assistant Secretary for Planning and Evaluation

# **National Alzheimer's Project Act**

## **Goal**

**To effectively treat Alzheimer's  
disease (delay onset, slow  
progression) by  
2025**

# **US National Alzheimer's Plan Goals**

- 1. Prevent and effectively treat AD by 2025**
- 2. Enhance care quality and efficiency**
- 3. Expand supports for people with AD and families.**
- 4. Enhance public awareness/engagement**
- 5. Improve data to track progress**

# Research Goal

- 1. Identify research priorities and milestones**
- 2. Expand research aimed at prevention and treatment of AD**
- 3. Accelerate efforts to identify early and presymptomatic stages of AD**
- 4. Coordinate research with international public and private entities**
- 5. Facilitate translation of findings into medical practice and public health programs**

# **White House Proposal for \$80 Million Additional AD Funding in FY 2013**

---

**NIH is using the following process to ensure timely and most effective spending of the anticipated \$80M in additional funding for AD research next year:**


- Representatives from several NIH ICs worked together to identify areas of highest need/opportunity, informed by the Alzheimer's Summit and other input.**
- NIA took the lead on developing FOA concepts for presentation at NACA in September 2012.**
- Extra funding will allow NIH to support more grants through these or existing FOAs and/or investigator-initiated research.**

# **NAPA Implementation**

- **NIH Summit on Alzheimer's Disease**
- **University of Pennsylvania State of Science**
- **Alzheimer's Association Expert Committee**

# **Alzheimer's Disease Research Summit 2012: Path to Treatment and Prevention**

May 14-15, 2012  
National Institutes of Health  
Bethesda, MD



# Summit on Non-AD Dementias

- May 1-2, 2013
- Frontotemporal lobar degenerations
- Dementia with Lewy bodies
- Vascular cognitive impairment
- Diagnostic issues
- Recommendations for National Plan

# International Partnerships

---

## Examples:

- 1) Meeting of international Alzheimer's research funders:  
Alzheimer's Association/National Institute on Aging  
July 15, 2012, Vancouver
- 2) Alzheimer's disease genetics - July 14, 2012, Vancouver
- 3) Biomarkers  
World-wide ADNI – July 13, 2012, Vancouver  
International CSF biomarkers cooperation
- 4) Common Alzheimer's Disease Research Ontology (CADRO, IADRP)
- 5) EU Joint Program on Neurodegenerative Diseases

# **Advisory Council Recommendations 2012**

- **Increase federal funding to \$2B**
- **HHS should update strategic plan**
- **Translate research into practice**
- **Compress therapeutic pipeline**
- **FDA should report to Advisory Council**
- **Metrics on impact of Plan**
- **Public-private partnerships**
- **Promote international collaborations**

# **National Plan to Address Alzheimer's Disease 2013**

- **Under construction, to be released around May, 2013**
- **Likely similar to the first plan**
- **Metrics developed for measuring progress**
- **Expanded recommendations for 2013**
  - **Milestones recommended**

# **Advisory Council Recommendations 2013**

- **Reemphasize need for \$2B/year**
- **HHS should regularly monitor progress and update research plan**
- **Translate research into clinical practice mindful of issues concerning disparities**
- **Compress therapeutic pipeline**
  - **NYAS, CEO leadership group, Alz Assoc**
- **Emphasize public-private partnerships**
- **Develop and refine metrics on economic impact**

# **Advisory Council Recommendations 2013**

- **Develop Global Alzheimer's Action Plan**
- **Recommend Administration develop Office in White House/HHS for AD Plan**
- **Launch national campaign for awareness and early detection**
- **Gather data on Annual Medicare Wellness Visit**

# National Alzheimer's Plan



- **ASPE will load the National Alzheimer's Plan into the new web-based tool this summer.**
- **HHS agencies will be able to enter their progress on action steps for which they are responsible. The tool will facilitate reporting by HHS agencies.**
- **ASPE will be able to create and share reports on progress across action steps for all partners – as well as identify any action steps that are outstanding.**
- **Indicators of progress can be linked to a broader set of HHS measures, to connect our effort to those of others across the Department.**